506U78 in Treating Patients With Recurrent or Refractory Cutaneous
T-cell Lymphoma
This study is no longer recruiting patients.
Sponsored by: |
M.D. Anderson Cancer Center
|
Information provided by: |
National Cancer Institute (NCI) |
Purpose
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of 506U78 in treating patients who have recurrent or refractory cutaneous
T-cell lymphoma.
Condition
|
Treatment or Intervention |
Phase |
recurrent cutaneous T-cell lymphoma recurrent mycosis fungoides/Sezary syndrome
|
Drug: 506U78 Procedure: chemotherapy
|
Phase II
|
MedlinePlus related topics: Lymphoma
Study Type: Interventional
Study Design: Treatment
Official Title: Phase II Study of 506U78 in Patients With Recurrent or Refractory Cutaneous T-Cell Lymphoma
Further Study Details:
OBJECTIVES:
- Determine the response rate, failure-free survival, and progression-free survival of patients with recurrent or refractory
cutaneous T-cell lymphoma treated with 506U78.
- Determine the toxicity of this drug in these patients
- Study the pharmacokinetics of this drug in these patients.
OUTLINE: This is a multicenter study.
Patients receive 506U78 IV over 2 hours on days 1, 3, and 5. Treatment continues every 28 days for up to 6 courses in the
absence of disease progression or unacceptable toxicity.
Patients are followed every 6 months.
PROJECTED ACCRUAL: A total of 12-35 patients will be accrued for this study within 3 years.
Eligibility
Ages Eligible for Study:
16 Years and above,
Genders Eligible for Study:
Both
DISEASE CHARACTERISTICS:
- Histologically confirmed relapsed or refractory cutaneous T-cell lymphoma
- Large cell transformation of cutaneous T-cell lymphoma allowed
- No active CNS disease
PATIENT CHARACTERISTICS: Age:
Performance status:
Life expectancy:
Hematopoietic:
- Absolute neutrophil count at least 1,000/mm^3*
- Platelet count at least 100,000/mm^3* NOTE: *Unless attributable to marrow or splenic involvement by lymphoma
Hepatic:
- Bilirubin no greater than 1.5 times upper limit of normal (ULN)
- SGPT no greater than 2.5 times ULN
Renal:
- Creatinine clearance greater than 50 mL/min
Cardiovascular
- No history of symptomatic cardiac dysfunction
- No history of pericardial effusion
Other:
- HIV negative
- No grade 2 or greater sensory or motor neuropathy
- No history of seizures
- No other malignancy within the past 5 years except curatively treated basal cell carcinoma of the skin of carcinoma in situ
of the cervix
- No medical, psychiatric, or social condition that would preclude study
- No other concurrent serious illness or active infection
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
PRIOR CONCURRENT THERAPY: Biologic therapy:
- No prior stem cell or bone marrow transplantation (BMT)
- No more than 1 prior immunotherapy regimen
- No more than 3 prior systemic regimens with denileukin diftitox
- At least 3 weeks since prior biologic therapy
- No concurrent BMT
Chemotherapy:
- No prior 506U78
- No more than 3 prior systemic chemotherapy regimens comprising any of the following:
- Oral methotrexate
- Topical mechlorethamine
- At least 3 weeks since prior chemotherapy
- No other concurrent chemotherapy
Endocrine therapy:
- At least 3 weeks since prior anticancer endocrine therapy
- No concurrent topical or systemic steroids
Radiotherapy:
- At least 3 weeks since prior radiotherapy
- No more than 3 prior systemic regimens comprising any of the following:
- Total skin electron beam therapy
- Spot radiotherapy
Surgery:
Other:
- No more than 3 prior systemic regimens comprising any of the following:
- Oral retinoids
- Ultraviolet therapy (PUVA)
- At least 3 weeks since prior anticancer therapy
Location
Information
Texas CCOP - M.D. Anderson Research Base, Houston,
Texas,
77030-4009,
United States
University of Texas - MD Anderson Cancer Center, Houston,
Texas,
77030-4009,
United States
Study chairs or principal investigators
Andre Goy, MD, Study Chair, M.D. Anderson Cancer Center
More Information
Clinical trial summary from the National Cancer Institute's PDQ® database
Study ID Numbers:
CDR0000067970; MDA-ID-99213; NCI-86
Record last reviewed:
March 2003
Record first received:
July 5, 2000
ClinicalTrials.gov Identifier:
NCT00005982Health Authority: Unspecified
ClinicalTrials.gov processed this record on 2004-10-22